Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach Mete Saylan, MD, M.J. Treur, R. Postema, N. Dilbaz, H. Savas, B.M. Heeg, P.B. Drost Value in Health Regional Issues Volume 2, Issue 2, Pages 171-180 (September 2013) DOI: 10.1016/j.vhri.2013.06.004 Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 1 Schematic model representation. Value in Health Regional Issues 2013 2, 171-180DOI: (10.1016/j.vhri.2013.06.004) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 2 Treatment sequence strategies. T3, triiodothyronine. Value in Health Regional Issues 2013 2, 171-180DOI: (10.1016/j.vhri.2013.06.004) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 3 Time until next episode per number of prior episodes. Data points are from Solomon et al. [35]. Lines represent Weibul survival curve fits. Value in Health Regional Issues 2013 2, 171-180DOI: (10.1016/j.vhri.2013.06.004) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 4 Scatter plot of comparison adjunctive aripiprazole with adjunctive quetiapine and adjunctive olanzapine. QALY, quality-adjusted life-year; TL, Turkish lira. Value in Health Regional Issues 2013 2, 171-180DOI: (10.1016/j.vhri.2013.06.004) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 5 Cost-effectiveness acceptability curves. QALY, quality-adjusted life-year; TL, Turkish lira. Value in Health Regional Issues 2013 2, 171-180DOI: (10.1016/j.vhri.2013.06.004) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions